Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Psoriasis affecting the hands and feet can be difficult to distinguish clinically from eczema. Unfortunately, a biopsy of an area thought to be volar psoriasis is of little diagnostic value, as it is ...

In the smaller subset of patients with hand/foot psoriasis, treatment with icotrokinra showed a numerically higher rate of skin clearance at Week 16, which increased through Week 52 with patients ...

Psoriasis is an autoimmune disease that causes red, flaky patches on the skin. It frequently occurs on the bottoms of the feet. The American Podiatric Medical Association offers suggestions for ...